Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly

Trial Profile

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Acronyms URGE
  • Most Recent Events

    • 17 Feb 2017 Planned End Date changed from 1 May 2016 to 1 Dec 2017.
    • 17 Feb 2017 Planned primary completion date changed from 1 May 2016 to 1 Dec 2017.
    • 17 Feb 2017 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top